ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Tomasi To Resign As Roswell Park President; Committee To Study NIH Grant Review Issues

December 15, 1995

University Of Illinois Cancer Center Director Kruh Dies

January 7, 2011

HHS Inspector General: Busy Signals Greet One In Three Callers To 800-4-CANCER

July 24, 1998

Semantics: NIH to Drop “Alternative From Center’s Name; Integrative Better Describes Current Focus

June 6, 2014

In Brief: Michael Friedman to Retire as CEO of City of Hope

March 1, 2013

Questions Raised By Committee Kills Still Not Resolved

July 29, 1977